PRPO
Precipio, Inc. NASDAQ Listed Jun 30, 2017$27.40
+4.90%
vs $26.12
Mkt Cap $48.9M
52w Low $16.00
64.7% of range
52w High $33.63
50d MA $24.93
200d MA $25.09
P/E (TTM)
—
EV/EBITDA
154.4x
P/B
3.0x
Debt/Equity
0.2x
ROE
-2.5%
P/FCF
122.5x
RSI (14)
62.80
ATR (14)
$2.30
Beta
1.20
50d MA
$24.93
200d MA
$25.09
Avg Volume
143.7K
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
4 Science Park · New Haven, CT 06511 · US
Data updated apr 26, 2026 8:49pm
· Source: financialmodelingprep.com